



Resource impact template

Resource impact

Published: 11 February 2026

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for hormone-relapsed metastatic prostate cancer:

- [Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer](#) (2026) NICE technology appraisal guidance 1130
- [Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer](#) (2024) NICE technology appraisal guidance 951